A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.
- 15 May 2017 New trial record